Zepbound vs Mounjaro Cost: Same Drug, Different Insurance Math
Zepbound and Mounjaro are both tirzepatide from Eli Lilly. Mounjaro (diabetes) is often covered by insurance including Medicare; Zepbound (weight loss) faces the Medicare exclusion. Your diagnosis drives your cost. Because Medicare and many plans cover diabetes drugs but exclude weight-loss drugs, Mounjaro is often covered when Zepbound is not, even though both contain identical tirzepatide made by the same manufacturer.
- Zepbound and Mounjaro are the same molecule (tirzepatide) at identical doses.
- Mounjaro is approved for type 2 diabetes; Zepbound for weight management and sleep apnea.
- Medicare covers Mounjaro for diabetes but excludes Zepbound for weight loss.
- Your diagnosis, not your goal, often determines which brand insurance will pay for.
The same molecule
Zepbound and Mounjaro both contain tirzepatide, made by Eli Lilly, at the same doses. Pharmacologically they are identical. The difference is entirely regulatory: they are separate FDA approvals for separate indications, and that distinction drives coverage and cost.
Mounjaro is approved for type 2 diabetes; Zepbound for chronic weight management and, more recently, obstructive sleep apnea in adults with obesity. Same drug, two labels.
Why coverage differs
The coverage gap follows the indication. Medicare Part D covers Mounjaro for type 2 diabetes because diabetes drugs are not subject to the statutory weight-loss exclusion. Zepbound, indicated for weight loss, falls under that exclusion and is not covered by Medicare for obesity.
Commercial plans mirror this logic: many cover Mounjaro for a diabetes diagnosis while excluding Zepbound for weight loss, even though the molecule is the same. A patient with both type 2 diabetes and obesity may find Mounjaro dramatically cheaper through insurance.
| Attribute | Zepbound | Mounjaro |
|---|---|---|
| Molecule | Tirzepatide | Tirzepatide (identical) |
| Indication | Weight, sleep apnea | Type 2 diabetes |
| List price | ~$1,086 | ~$1,069 |
| Medicare | Excluded for weight loss | Covered for diabetes |
The cost in practice
List prices are similar — Mounjaro around $1,069 and Zepbound around $1,086 per month. But list price is rarely what patients pay. With diabetes coverage, Mounjaro can cost a modest copay. Without weight-loss coverage, Zepbound may cost full self-pay unless you use LillyDirect, which offers Zepbound vials from about $299 per month.
The practical consequence is that the same molecule can cost $25 or $1,086 depending solely on your diagnosis and which brand your prescriber codes.
| Situation | Likely best option |
|---|---|
| Type 2 diabetes | Mounjaro (often covered) |
| Obesity, no diabetes | Zepbound or compounded |
| Cash-pay, cost-first | Compounded tirzepatide |
Where compounded fits
Compounded tirzepatide is a separate, non-FDA-approved category priced at $199 to $297 per month — far below either brand’s list. It carries none of the SURMOUNT or SURPASS trial evidence and is legally restricted after the 2025 shortage resolution.
For a cash-pay patient without diabetes coverage, compounded tirzepatide is often the cheapest route, while brand Mounjaro through diabetes coverage is cheapest for those who qualify. The right answer depends on your insurance and diagnosis.
Frequently asked questions
Are Zepbound and Mounjaro the same drug?
Yes, both are tirzepatide from Eli Lilly at identical doses. They differ only in FDA-approved indication and therefore in insurance coverage.
Why is Mounjaro often cheaper for me?
If you have type 2 diabetes, Mounjaro is covered by Medicare and many commercial plans, while Zepbound for weight loss faces the Medicare exclusion.
Can I use Mounjaro for weight loss?
That is an off-label decision for your prescriber. Coverage is tied to the diabetes indication; using it off-label may affect what insurance pays.
Sources
- FDA — human drug compounding and GLP-1 status.
- Manufacturer and CMS coverage information, captured July 2026.
- Evidence ledger: evidence-ledger.csv.